Cargando…

Use of intravenous immunoglobulin in the Department of Neurology at Ninewells Hospital, 2008–2009: Indications for utilization and cost-effectiveness

This study was designed to identify the indications for prescription of intravenous immunoglobulin (IVIg) in neurology and the cost effectiveness of this therapy. OBJECTIVES: IVIg is a relatively costly therapy and the annual budget spent on providing this therapy for various indications at Ninewell...

Descripción completa

Detalles Bibliográficos
Autores principales: O’ Riordan, Jonathan, Swingler, Robert J., Malek, Naveed M.
Formato: Texto
Lenguaje:English
Publicado: Medknow Publications 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3021930/
https://www.ncbi.nlm.nih.gov/pubmed/21264135
http://dx.doi.org/10.4103/0972-2327.74199
_version_ 1782196447291113472
author O’ Riordan, Jonathan
Swingler, Robert J.
Malek, Naveed M.
author_facet O’ Riordan, Jonathan
Swingler, Robert J.
Malek, Naveed M.
author_sort O’ Riordan, Jonathan
collection PubMed
description This study was designed to identify the indications for prescription of intravenous immunoglobulin (IVIg) in neurology and the cost effectiveness of this therapy. OBJECTIVES: IVIg is a relatively costly therapy and the annual budget spent on providing this therapy for various indications at Ninewells Hospital was close to £1.5 million. In today’s economic times, a cost–benefit analysis of all therapies is prudent. This is of relevance to countries in the developing world as well where perhaps not everybody could afford such cost-intensive therapy. MATERIALS AND METHODS: We audited 2 time periods over 12 months each in 2004–2005 and 2008–2009 to look at the patterns of utilization of IVIg over these periods. We searched the literature for alternative and cost-effective therapies for the most common indications for use of IVIg. RESULTS: Fiscal costs on prescription of IVIg have rocketed up by almost 300% in this Neurology Department comparing data from 2004–2005 vs 2008–2009 and this is disproportionate to the increase in the annual admission rate (bed usage), partly because of the soaring costs of the drug available in the market and also because of the increased prescription of IVIg for numerous indications where clinical trials data are yet not so robust. CONCLUSION: We have looked at the cost of alternative therapies and offer some proposals that if implemented could potentially save £330,000 annually from the health budget at this NHS Trust. Perhaps similar models could evolve for better cost-effective utilization of IVIg in countries in the developing world where health budgeting is more acutely relevant.
format Text
id pubmed-3021930
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Medknow Publications
record_format MEDLINE/PubMed
spelling pubmed-30219302011-01-24 Use of intravenous immunoglobulin in the Department of Neurology at Ninewells Hospital, 2008–2009: Indications for utilization and cost-effectiveness O’ Riordan, Jonathan Swingler, Robert J. Malek, Naveed M. Ann Indian Acad Neurol Original Article This study was designed to identify the indications for prescription of intravenous immunoglobulin (IVIg) in neurology and the cost effectiveness of this therapy. OBJECTIVES: IVIg is a relatively costly therapy and the annual budget spent on providing this therapy for various indications at Ninewells Hospital was close to £1.5 million. In today’s economic times, a cost–benefit analysis of all therapies is prudent. This is of relevance to countries in the developing world as well where perhaps not everybody could afford such cost-intensive therapy. MATERIALS AND METHODS: We audited 2 time periods over 12 months each in 2004–2005 and 2008–2009 to look at the patterns of utilization of IVIg over these periods. We searched the literature for alternative and cost-effective therapies for the most common indications for use of IVIg. RESULTS: Fiscal costs on prescription of IVIg have rocketed up by almost 300% in this Neurology Department comparing data from 2004–2005 vs 2008–2009 and this is disproportionate to the increase in the annual admission rate (bed usage), partly because of the soaring costs of the drug available in the market and also because of the increased prescription of IVIg for numerous indications where clinical trials data are yet not so robust. CONCLUSION: We have looked at the cost of alternative therapies and offer some proposals that if implemented could potentially save £330,000 annually from the health budget at this NHS Trust. Perhaps similar models could evolve for better cost-effective utilization of IVIg in countries in the developing world where health budgeting is more acutely relevant. Medknow Publications 2010 /pmc/articles/PMC3021930/ /pubmed/21264135 http://dx.doi.org/10.4103/0972-2327.74199 Text en © Annals of Indian Academy of Neurology http://creativecommons.org/licenses/by/2.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
O’ Riordan, Jonathan
Swingler, Robert J.
Malek, Naveed M.
Use of intravenous immunoglobulin in the Department of Neurology at Ninewells Hospital, 2008–2009: Indications for utilization and cost-effectiveness
title Use of intravenous immunoglobulin in the Department of Neurology at Ninewells Hospital, 2008–2009: Indications for utilization and cost-effectiveness
title_full Use of intravenous immunoglobulin in the Department of Neurology at Ninewells Hospital, 2008–2009: Indications for utilization and cost-effectiveness
title_fullStr Use of intravenous immunoglobulin in the Department of Neurology at Ninewells Hospital, 2008–2009: Indications for utilization and cost-effectiveness
title_full_unstemmed Use of intravenous immunoglobulin in the Department of Neurology at Ninewells Hospital, 2008–2009: Indications for utilization and cost-effectiveness
title_short Use of intravenous immunoglobulin in the Department of Neurology at Ninewells Hospital, 2008–2009: Indications for utilization and cost-effectiveness
title_sort use of intravenous immunoglobulin in the department of neurology at ninewells hospital, 2008–2009: indications for utilization and cost-effectiveness
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3021930/
https://www.ncbi.nlm.nih.gov/pubmed/21264135
http://dx.doi.org/10.4103/0972-2327.74199
work_keys_str_mv AT oriordanjonathan useofintravenousimmunoglobulininthedepartmentofneurologyatninewellshospital20082009indicationsforutilizationandcosteffectiveness
AT swinglerrobertj useofintravenousimmunoglobulininthedepartmentofneurologyatninewellshospital20082009indicationsforutilizationandcosteffectiveness
AT maleknaveedm useofintravenousimmunoglobulininthedepartmentofneurologyatninewellshospital20082009indicationsforutilizationandcosteffectiveness